Novamind Inc. announced it will host a phase I randomized clinical trial for adults with opioid use disorder. The study will investigate the safety and efficacy of ketamine-assisted psychotherapy combined with Mindfulness-Oriented Recovery Enhancement therapy (the "MORE+KAP Clinical Trial"). Recent studies have shown promise for the use of ketamine in treating substance use disorders, including alcohol and cocaine use disorders.

With opioid-related deaths continuing to rise across nearly all populations age 15 and older, the MORE+KAP Clinical Trial comes at a critical time and makes an important contribution to the early evidence base for effective treatment options.